The global attention deficit hyperactivity disorder market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising R&D activities, product launches around the world, and approval of new drugs.
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder. In this disorder the patient becomes impulsive, hyperactive, and lacks attention. ADHD is common and chronic disorder in which an individual’s ability to focus, self-control and perform other important skills in daily life are impacted. In other word we can also say that ADHD is caused due to biochemical connectivity and the structural difference in the mind.
Attention deficit hyperactivity disorder can be found in children and adults where symptoms generally begin in childhood. Based on survey conducted by National Survey Children Health (NSCH), in 2016, around 6 million children reported to be suffering from ADHD. The cause of this disorder is not yet known but factors like exposure of toxins, genes, pre-natal brain injuries are projected to be responsible for ADHD.
Awareness of mental health is increasing among people due to rising government initiatives which aids the ADHD market expansion. Globally, government is taking required steps to address ADHD condition as number patients suffering from mental disorders, including ADHD disorder, is increasing. The U.S. Department of Health & Human Services, in 2016, awarded the Substance Abuse and Mental Health Services Administration (SAMHSA) with USD 54 million for addressing the requirements of an individual’s having serious mental illnesses.
In the same way, in 2016, the National Health Services (NHS) England, set five-year plan for mental health. In which government is investing around USD 1.25 billion. Hence, government support coupled with increasing awareness is projected to support the expansion of ADHD market. Commercialization of drugs and approval for new drugs are serving the market.
Market Trends, Drivers, Restraints, and Opportunities
- The growing prevalence of attention deficit hyperactivity disorder is major factor responsible for propelling the market growth in the coming years.
- Changing lifestyle, increasing awareness among people, and rising number of researches in neuroscience are anticipated to boost the market growth over the forecast period.
- Rise in the number of premature babies, and increasing advancement in medical field are projected to fuel the market expansion.
- Increasing adoption of generic medication, and launch of novel drugs which are patient-specific ADHD drugs are expected to drive the growth of the market in coming years.
- Complementary and alternative therapies such as special diets, vitamins, minerals, and herbs, and side effected of ADHD drugs are anticipated to hamper the market growth over the forecast period.
Scope of Attention Deficit Hyperactivity Disorder Market Report
The report on the global attention deficit hyperactivity disorder market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attention Deficit Hyperactivity Disorder Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Drug Types (Stimulant [Amphetamine, Methylphenidate, Lisdexamfetamine, and Dexmethylphenidate] and Non-stimulant [Atomoxetine, Guanfacine, Clonidine, and Bupropion]), Demographic (Adult and Children), Distribution Channels (Hospital Pharmacy and Retail Pharmacy)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Eli Lily & Company; Pfizer; Johnson & Johnson Services LLC; Lupin; Shire; Mallinckrodt, Prude Pharma L.P.; and NEOS Therapeutics Inc.
Attention Deficit Hyperactivity Disorder Market Segment Insights
Non-stimulant segment is expected to expand at a rapid pace
On the basis of drug types, the attention deficit hyperactivity disorder market is divided into stimulants and non-stimulants. The stimulant segment is subdivided into amphetamine, methylphenidate, lisdexamfetamine, and dexmethylphenidate. The non-stimulant segment is further subdivided into atomoxetine, guanfacine, clonidine, and bupropion.
The stimulant segment is expected to account for a key share of the market during the forecast period owing to increasing government initiatives and ongoing clinical trials. Moreover, demand of stimulant drugs is rising because of its effectiveness for the treatment of ADHD disease which is fueling the segment growth in coming years. Tris Pharma, Inc., in April 2016, launched its Dyanavel XR (amphetamine) which is FDA-approved liquid ADHD medication for the treatment of patients above the age of six.
However, the non-stimulant segment is anticipated to expand at a rapid pace during the forecast period owing to their long-lasting effect as compared to stimulants. The non-stimulant drugs does not have risk of substance abuse is major factor for propelling the segment growth. Also, development of non-stimulant drugs for ADHD, and rising number of market players are expected to drive the growth of the segment.
Adults segment is projected to hold a major market share
In terms of demographics, the market is segmented into children (2-17 years of age) and adults (aged 18 and above). The adult segment is expected to hold a key share of the market in the coming years due to large patient population. Based on ADD Health and Wellness Centers, Inc., in the U.S., ADHD affects more than 4.0% of the adult population. Based on the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA), in 2015, around 17 million people used stimulants out of which 5 million were adults (age 18-25) and only 2 million were youth (age 12-17).
Retail pharmacy segment is anticipated to expand at a substantial CAGR
Based on distribution channels, the attention deficit hyperactivity disorder market is bifurcated into hospital pharmacy and retail pharmacy. The retail pharmacy segment is expected to hold a key share of the market during the forecast period owing to growing inpatient care initiatives and rising number of prescriptions.
Due to extensive nature of the treatment of the condition, the ADHD inpatients are less in number as compared to number of patient in-home care. Patients prefers retail pharmacies than hospitals for purchasing drugs. Hence, the segment is projected to maintain its dominance and also expected to expand at a substantial CAGR during the forecast period.
North America is expected to dominate the market
On the basis of regions, the attention deficit hyperactivity disorder market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increase in number of drug prescriptions each year. Furthermore, rising product launches and increasing collaboration among market players for product development are expected to fuel the market growth.
In the U.S., in August 2017, Shire launched a novel drug MYDAYIS (latest formulation of Adderall). In October 2018, Dr. Reddy laboratories, launched the atomoxetine capsules in the U.S. for the treatment of ADHD. Therefore, commercialization of products is anticipated to drive the regional market.
On the other hand, the market of Europe is expected to exhibit a rapid growth rate in the coming years owing to increasing prevalence of ADHD, improving coverage for treatment of the condition, rising awareness of mental health, and high consumption of addictive and preservatives.
The global attention deficit hyperactivity disorder market has been segmented on the basis of
- Hospital Pharmacy
- Retail Pharmacy
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Eli Lily & Company
- Johnson & Johnson Services LLC
- Prude Pharma L.P
- NEOS Therapeutics Inc.
Key players competing in the attention deficit hyperactivity disorder market are Eli Lily & Company; Pfizer; Johnson & Johnson Services LLC; Lupin; Shire; Mallinckrodt, Prude Pharma L.P.; and NEOS Therapeutics Inc. Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.